Drug · CHEMBL820
BUSULFAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BUSULFAN. Drugs and targets, record CHEMBL820. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL820
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Busulfano, Busulfanum, Leucosulfan, Myelosan, Myelosanum, NCI-C01592, NSC-750, Sulphabutin
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases116
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 116Source Open Targets
See all 116 diseasesTrials531
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00049517 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | Phase 3 | 657 | 2013-02-12 | busulfan | Its name | ClinicalTrials.gov |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | Phase 2 | 422 | 2022-08-05 | busulfan | Its name | ClinicalTrials.gov |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | Phase 2/3 | 361 | 2021-08-13 | busulfan | Its name | ClinicalTrials.gov |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | 330 | 2021-01-22 | busulfan | Its name | ClinicalTrials.gov | |
| NCT01339910 | Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) | Phase 3 | 272 | 2018-05-30 | busulfan | Its name | ClinicalTrials.gov |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | Phase 2 | 260 | 2023-05-10 | busulfan | Its name | ClinicalTrials.gov |
| NCT01471444 | Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | Phase 3 | 256 | 2021-12-16 | busulfan | Its name | ClinicalTrials.gov |
| NCT00469144 | IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | Phase 3 | 233 | 2021-01-19 | busulfan | Its name | ClinicalTrials.gov |
| NCT00948090 | PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients | Phase 2 | 207 | 2014-07-31 | busulfan | Its name | ClinicalTrials.gov |
| NCT01413178 | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | Phase 3 | 205 | 2020-04-21 | busulfan | Its name | ClinicalTrials.gov |
1 to 10 of 531
See all 531 trialsComparisons in its trials74
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Daunorubicin (Induction Therapy) vs High Dose Daunorubicin (Induction Therapy): serious adverse events | 328 of 328 | 325 of 325 | 653 | NCT00049517 | Trial comparisons |
| Myeloablative Conditioning Regimen (MAC) vs Reduced Intensity Conditioning (RIC): Number of Participants With Primary Graft Failure | 1 of 132 | 3 of 133 | 265 | NCT01339910 | Trial comparisons |
| Myeloablative Conditioning Regimen (MAC) vs Reduced Intensity Conditioning (RIC): Number of Participants With Secondary Graft Failure | 1 of 132 | 4 of 133 | 265 | NCT01339910 | Trial comparisons |
| Myeloablative Conditioning Regimen (MAC) vs Reduced Intensity Conditioning (RIC): serious adverse events | 21 of 132 | 16 of 133 | 265 | NCT01339910 | Trial comparisons |
| Arm A (Flu+Bu) vs Arm B (Flu+Clo+Bu): Number of Participants in the Study Who Are With no Grade 3 or 4 Acute Graft-versus-host Disease at Any Time During the First 100 Days Post Transplant. | 125 of 130 | 115 of 120 | 250 | NCT01471444 | Trial comparisons |
| Arm A (Flu+Bu) vs Arm B (Flu+Clo+Bu): Number of Participants With Non Relapse Mortality at 100 Day Post Transplant | 3 of 130 | 6 of 120 | 250 | NCT01471444 | Trial comparisons |
| Arm A (Flu+Bu) vs Arm B (Flu+Clo+Bu): deaths from any cause | 67 of 130 | 59 of 120 | 250 | NCT01471444 | Trial comparisons |
| Arm A (Flu+Bu) vs Arm B (Flu+Clo+Bu): serious adverse events | 25 of 130 | 39 of 120 | 250 | NCT01471444 | Trial comparisons |
| Fixed-Dose Busulfan + Fludarabine vs Adjusted Dose Busulfan + Fludarabine: serious adverse events | 2 of 114 | 3 of 111 | 225 | NCT00469144 | Trial comparisons |
| Busulfan + Melphalan vs Melphalan: Overall Survival (OS) | 91 of 104 | 79 of 98 | 202 | NCT01413178 | Trial comparisons |
1 to 10 of 74
See all 74 comparisons in its trialsPapers from its trials251
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL820
GET https://conductscience.org/api/drugs/v1/CHEMBL820/diseases?page=2